Outstanding Q3 results and raised outlooks are drawing investor attention towards
Bristol Myers Squibb (BMY). Solid earnings, driven by sales of older drugs and new introductions, along with strong demand for blood thinner medicines have contributed to increased shares. Jim Cramer, the investment guru, has strongly recommended the purchase of
BMY shares. The company displays potential due to several strategic acquisitions and positive results in the biotech market.
BMY's CAR T Cell therapies gained approval from the US FDA, contributing to the stock's reputation. Despite some dips in stock performance,
BMY's overall trend shows promise. Also, an impressive 77% institutional ownership indicates the interest from heavy market players. While the company has beat a $6.4 billion lawsuit over a delayed cancer drug, it's gearing up to launch cost-cuts while posting quarterly losses. Looking at the future, the market welcomes the robust Q3 2024 growth posted by Bristol Myers Squibb.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 09 Nov 2024 15:24:11 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 3
